XML 118 R86.htm IDEA: XBRL DOCUMENT v3.20.4
Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)
1 Months Ended 12 Months Ended
Oct. 31, 2020
shares
Sep. 30, 2020
shares
Jul. 31, 2018
USD ($)
day
$ / shares
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Debt Instrument [Line Items]              
Proceeds from long-term debt, net of issuance costs       $ 0 $ 376,000 $ 219,859,000  
Equity component of convertible debt, net of issuance costs and deferred taxes           36,868,000  
Deferred income taxes       (156,000) (3,674,000) (21,278,000)  
Interest payable       3,500,000      
Long-term debt       171,882,000 217,991,000    
Convertible debt              
Debt Instrument [Line Items]              
Long-term debt       168,147,000 213,771,000    
Convertible debt | Precigen ActoBio, Inc. | Harvest Intrexon Enterprise Fund I, LP              
Debt Instrument [Line Items]              
Debt instrument, interest rate, stated percentage             3.00%
Interest expense       $ 616,000 921,000 290,000  
Notes payable to banks | Trans Ova Genetics, LC | American State Bank              
Debt Instrument [Line Items]              
Debt instrument, interest rate, stated percentage       3.95%      
Long-term debt       $ 3,655,000      
Debt instrument, periodic payment       39,000      
3.5% Convertible Notes Due 2023              
Debt Instrument [Line Items]              
Aggregate principal amount     $ 200,000,000 200,000,000      
Proceeds from long-term debt, net of issuance costs     193,958,000        
Debt issuance costs     $ 6,042,000        
Debt instrument, interest rate, stated percentage     3.50%        
Conversion rate     58.6622        
Principal amount used in conversion     $ 1,000        
Conversion price (in usd per share) | $ / shares     $ 17.05        
Debt instrument redemption price, percentage     100.00%        
Carrying value of convertible debt     $ 143,723,000 $ 168,147,000 $ 157,560,000    
Equity component of convertible debt, net of issuance costs and deferred taxes     50,235,000        
Deferred income taxes     $ 13,367,000        
Effective interest rate on convertible notes       11.02%      
Convertible notes, unamortized discount and issuance costs       $ 31,853,000      
3.5% Convertible Notes Due 2023 | Minimum              
Debt Instrument [Line Items]              
Common stock price trading days | day     20        
Common stock price consecutive trading days | day     30        
Percentage of common share price over conversion price for conversion     130.00%        
3.5% Convertible Notes Due 2023 | Maximum              
Debt Instrument [Line Items]              
Common stock price trading days | day     5        
Common stock price consecutive trading days | day     5        
Debt instrument redemption price, percentage     98.00%        
Merck Convertible Note              
Debt Instrument [Line Items]              
Aggregate principal amount           $ 25,000,000  
Common stock issued upon conversion of long-term debt (in shares) | shares 6,758,400            
Debt instrument, resale restriction days 180 days            
ActoBio Notes              
Debt Instrument [Line Items]              
Common stock issued upon conversion of long-term debt (in shares) | shares   6,293,402          
Harvest Intrexon Enterprise Fund I, LP | Precigen ActoBio, Inc.              
Debt Instrument [Line Items]              
Aggregate principal amount             $ 30,000,000